Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Improving transparency and scientific rigor in academic publishing.

Prager EM, Chambers KE, Plotkin JL, McArthur DL, Bandrowski AE, Bansal N, Martone ME, Bergstrom HC, Bespalov A, Graf C.

Brain Behav. 2018 Dec 2:e01141. doi: 10.1002/brb3.1141. [Epub ahead of print]

2.

Improving transparency and scientific rigor in academic publishing.

Prager EM, Chambers KE, Plotkin JL, McArthur DL, Bandrowski AE, Bansal N, Martone ME, Bergstrom HC, Bespalov A, Graf C.

J Neurosci Res. 2018 Dec 2. doi: 10.1002/jnr.24340. [Epub ahead of print]

PMID:
30506706
3.

Industry is more alarmed about reproducibility than academia.

Bespalov A, Barnett AG, Begley CG.

Nature. 2018 Nov;563(7733):626. doi: 10.1038/d41586-018-07549-w. No abstract available.

PMID:
30487623
4.

Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats.

Sukhanov I, Dorotenko A, Dolgorukova A, Hoener MC, Gainetdinov RR, Bespalov AY.

Neuropharmacology. 2019 Jan;144:184-192. doi: 10.1016/j.neuropharm.2018.10.034. Epub 2018 Oct 24.

PMID:
30366004
5.

Breast and cervical cancer incidence and mortality trends in Russia 1980-2013.

Barchuk A, Bespalov A, Huhtala H, Chimed T, Laricheva I, Belyaev A, Bray F, Anttila A, Auvinen A.

Cancer Epidemiol. 2018 Aug;55:73-80. doi: 10.1016/j.canep.2018.05.008. Epub 2018 May 26.

PMID:
29843073
6.

Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction.

Vengeliene V, Takahashi TT, Dravolina OA, Belozertseva I, Zvartau E, Bespalov AY, Spanagel R.

Psychopharmacology (Berl). 2018 Jul;235(7):1955-1965. doi: 10.1007/s00213-018-4893-9. Epub 2018 Apr 12.

PMID:
29651507
7.

Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Barnes SA, Sheffler DJ, Semenova S, Cosford NDP, Bespalov A.

Biol Psychiatry. 2018 Jun 1;83(11):955-962. doi: 10.1016/j.biopsych.2018.03.001. Epub 2018 Mar 9. Review.

PMID:
29628194
8.

Targeting Glycine Reuptake in Alcohol Seeking and Relapse.

Vengeliene V, Roßmanith M, Takahashi TT, Alberati D, Behl B, Bespalov A, Spanagel R.

J Pharmacol Exp Ther. 2018 Apr;365(1):202-211. doi: 10.1124/jpet.117.244822. Epub 2018 Jan 24.

PMID:
29367277
9.

Lacking quality in research: Is behavioral neuroscience affected more than other areas of biomedical science?

Bespalov A, Steckler T.

J Neurosci Methods. 2018 Apr 15;300:4-9. doi: 10.1016/j.jneumeth.2017.10.018. Epub 2017 Oct 28.

PMID:
29107620
10.

Potential role of tyrosine hydroxylase in the loss of psychostimulant effect of amphetamine under conditions of impaired dopamine transporter activity.

Janenaite E, Vengeliene V, Bespalov A, Behl B.

Behav Brain Res. 2017 Sep 15;334:105-108. doi: 10.1016/j.bbr.2017.07.028. Epub 2017 Jul 24.

PMID:
28750831
11.

Novel reinforcement learning paradigm based on response patterning under interval schedules of reinforcement.

Schifani C, Sukhanov I, Dorofeikova M, Bespalov A.

Behav Brain Res. 2017 Jul 28;331:276-281. doi: 10.1016/j.bbr.2017.04.043. Epub 2017 Apr 27.

PMID:
28457882
12.

mGlu1 receptor as a drug target for treatment of substance use disorders: time to gather stones together?

Dravolina OA, Zvartau E, Danysz W, Bespalov AY.

Psychopharmacology (Berl). 2017 May;234(9-10):1333-1345. doi: 10.1007/s00213-017-4581-1. Epub 2017 Mar 11. Review.

PMID:
28285325
13.

Towards trans-diagnostic mechanisms in psychiatry: neurobehavioral profile of rats with a loss-of-function point mutation in the dopamine transporter gene.

Vengeliene V, Bespalov A, Roßmanith M, Horschitz S, Berger S, Relo AL, Noori HR, Schneider P, Enkel T, Bartsch D, Schneider M, Behl B, Hansson AC, Schloss P, Spanagel R.

Dis Model Mech. 2017 Apr 1;10(4):451-461. doi: 10.1242/dmm.027623. Epub 2017 Feb 6.

14.

Morphine-induced Straub tail reaction in mice treated with serotonergic compounds.

Belozertseva IV, Dravolina OA, Tur MA, Semina MG, Zvartau EE, Bespalov AY.

Eur J Pharmacol. 2016 Nov 15;791:1-7. doi: 10.1016/j.ejphar.2016.08.014. Epub 2016 Aug 24.

PMID:
27565217
15.

Theoretical Model to Explain Excess of Quasiparticles in Superconductors.

Bespalov A, Houzet M, Meyer JS, Nazarov YV.

Phys Rev Lett. 2016 Sep 9;117(11):117002. doi: 10.1103/PhysRevLett.117.117002. Epub 2016 Sep 9.

PMID:
27661716
16.

Enhanced brain penetration of hexamethonium in complexes with derivatives of fullerene C60.

Piotrovskiy LB, Litasova EV, Dumpis MA, Nikolaev DN, Yakovleva EE, Dravolina OA, Bespalov AY.

Dokl Biochem Biophys. 2016 May;468(1):173-5. doi: 10.1134/S1607672916030030. Epub 2016 Jul 15.

PMID:
27417712
17.

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets.

Bespalov A, Steckler T, Altevogt B, Koustova E, Skolnick P, Deaver D, Millan MJ, Bastlund JF, Doller D, Witkin J, Moser P, O'Donnell P, Ebert U, Geyer MA, Prinssen E, Ballard T, Macleod M.

Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.88. Epub 2016 Jun 17. No abstract available.

PMID:
27312728
18.

Drug Tolerance: A Known Unknown in Translational Neuroscience.

Bespalov A, Müller R, Relo AL, Hudzik T.

Trends Pharmacol Sci. 2016 May;37(5):364-378. doi: 10.1016/j.tips.2016.01.008. Epub 2016 Feb 28. Review.

PMID:
26935643
19.

Preclinical models of muscle spasticity: valuable tools in the development of novel treatment for neurological diseases and conditions.

Bespalov A, Mus L, Zvartau E.

Naunyn Schmiedebergs Arch Pharmacol. 2016 May;389(5):457-66. doi: 10.1007/s00210-016-1215-9. Epub 2016 Feb 10. Review.

PMID:
26861550
20.

The effects of PDE10 inhibition on attentional set-shifting do not depend on the activation of dopamine D1 receptors.

Nikiforuk A, Potasiewicz A, Rafa D, Drescher K, Bespalov A, Popik P.

Behav Pharmacol. 2016 Jun;27(4):331-8. doi: 10.1097/FBP.0000000000000201.

PMID:
26580130
21.

Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.

Wicke K, Haupt A, Bespalov A.

Expert Opin Investig Drugs. 2015;24(12):1515-28. doi: 10.1517/13543784.2015.1102884. Epub 2015 Nov 7. Review.

PMID:
26548316
22.

The Calpain Inhibitor A-705253 Attenuates Alcohol-Seeking and Relapse with Low Side-Effect Profile.

Vengeliene V, Moeller A, Meinhardt MW, Beardsley PM, Sommer WH, Spanagel R, Bespalov A.

Neuropsychopharmacology. 2016 Mar;41(4):979-88. doi: 10.1038/npp.2015.225. Epub 2015 Jul 28.

23.

The preclinical data forum network: A new ECNP initiative to improve data quality and robustness for (preclinical) neuroscience.

Steckler T, Brose K, Haas M, Kas MJ, Koustova E, Bespalov A; ECNP Preclinical Data Forum Network.

Eur Neuropsychopharmacol. 2015 Oct;25(10):1803-7. doi: 10.1016/j.euroneuro.2015.05.011. Epub 2015 Jun 4.

PMID:
26073278
24.

Agonist and antagonist effects of cytisine in vivo.

Radchenko EV, Dravolina OA, Bespalov AY.

Neuropharmacology. 2015 Aug;95:206-14. doi: 10.1016/j.neuropharm.2015.03.019. Epub 2015 Mar 31.

PMID:
25839895
25.

Combined exposure to hypercapnia and hypoxia provides its maximum neuroprotective effect during focal ischemic injury in the brain.

Tregub P, Kulikov V, Motin Y, Bespalov A, Osipov I.

J Stroke Cerebrovasc Dis. 2015 Feb;24(2):381-7. doi: 10.1016/j.jstrokecerebrovasdis.2014.09.003. Epub 2014 Dec 10.

PMID:
25498739
26.

[The role of VEGF, HSP-70 and protein S-100B in the potentiation effect of the neuroprotective effect of hypercapnic hypoxia].

Bespalov AG, Tregub PP, Kulikov VP, Pijanzin AI, Belousov AA.

Patol Fiziol Eksp Ter. 2014 Apr-Jun;(2):24-7. Russian.

PMID:
25318158
27.

Impaired cognition after stimulation of P2Y1 receptors in the rat medial prefrontal cortex.

Koch H, Bespalov A, Drescher K, Franke H, Krügel U.

Neuropsychopharmacology. 2015 Jan;40(2):305-14. doi: 10.1038/npp.2014.173. Epub 2014 Jul 15.

28.

Development of novel therapy of schizophrenia in children and adolescents.

Klein C, Bespalov A.

Expert Opin Investig Drugs. 2014 Nov;23(11):1531-40. doi: 10.1517/13543784.2014.933806. Epub 2014 Jun 27. Review.

PMID:
24970455
29.

Mechanistic insights into the analgesic efficacy of A-1264087, a novel neuronal Ca(2+) channel blocker that reduces nociception in rat preclinical pain models.

Zhu CZ, Vortherms TA, Zhang M, Xu J, Swensen AM, Niforatos W, Neelands T, Milicic I, Lewis LG, Zhong C, Gauvin D, Mikusa J, Zhan C, Pai M, Roderwald V, Chu KL, Cole EE, Bespalov A, Searle XB, McGaraughty S, Bitner RS, Jarvis MF, Bannon AW, Joshi SK, Scott VE, Lee CH.

J Pain. 2014 Apr;15(4):387.e1-14. doi: 10.1016/j.jpain.2013.12.002. Epub 2013 Dec 25.

PMID:
24374196
30.

[Comparative efficacy of hypoxia, hypercapnia and hypercapnic hypoxia increases body resistance to acute hypoxia in rats].

Kulikov VP, Tregub PP, Bespalov AG, Vvedenskiy AJ.

Patol Fiziol Eksp Ter. 2013 Jul-Sep;(3):59-61. Russian.

PMID:
24340622
31.

Neuroprotective effects of individual or combined exposure to hypoxia and hypercapnia in the experiment.

Tregub PP, Kulikov VP, Bespalov AG, Vvedensky AJ, Osipov IS.

Bull Exp Biol Med. 2013 Jul;155(3):327-9.

PMID:
24137595
32.

Tolerance to acute hypoxia maximally increases in case of joint effect of normobaric hypoxia and permissive hypercapnia in rats.

Tregub P, Kulikov V, Bespalov A.

Pathophysiology. 2013 Jun;20(3):165-70. doi: 10.1016/j.pathophys.2013.09.001. Epub 2013 Sep 29.

PMID:
24083870
33.

Development of disease-modifying treatment of schizophrenia.

Bespalov A, Klein C, Behl B, Gross G, Schoemaker H.

Handb Exp Pharmacol. 2012;(213):419-42. doi: 10.1007/978-3-642-25758-2_14. Review.

PMID:
23027423
34.

[Effect of Catechol-O-methyltransferase deficiency on reinforcing effects of cocaine (experimental study)].

Mus LV, Dravolina OA, Bespalov AIu, Käenmäki M, Talka R, Salminen O, Tuominen RK, Männistiö PT, Zvartau EE.

Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(7):48-52. Russian.

PMID:
23011431
35.

[Clinical signs of endothelial disorders in patients with severe sepsis].

Plotkin LL, Bespalov AM, Smirnov DM, Timchenko NN, Shapovalova IuS, Konradi AB.

Anesteziol Reanimatol. 2012 Mar-Apr;(2):48-51. Russian.

PMID:
22834288
36.

Nanocrystalline graphite films nucleation by the radio frequency bias pretreatment.

Dvorkin VV, Dzbanovsky NN, Krivchenko VA, Suetin NV, Rakhimov AT, Timofeyev MA, Bespalov AV, Golikova OL.

J Nanosci Nanotechnol. 2011 Oct;11(10):8912-6.

PMID:
22400280
37.

Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner.

Nikiforuk A, Kos T, Rafa D, Behl B, Bespalov A, Popik P.

Neuropharmacology. 2011 Jul-Aug;61(1-2):262-7. doi: 10.1016/j.neuropharm.2011.04.010. Epub 2011 Apr 21.

PMID:
21530555
38.

[Naltrexone and fluoxetine for maintenance of remission in patients with heroin addiction: a double-blind randomized placebo-controlled trial].

Krupitskiĭ EM, Zvartau EE, Tsoĭ-Podosenin MV, Masalov DV, Burakov AM, Egorova VIu, Didenko TIu, Romanova TN, Ivanova EB, Bespalov AIu, Verbitskaia EV, Neznanov NG, Grineneko AIa, O'Brien C, Woody D.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(5 Pt 2):44-54. Russian.

PMID:
21322147
39.

Antidepressant treatment in anxiety disorders.

Bespalov AY, van Gaalen MM, Gross G.

Curr Top Behav Neurosci. 2010;2:361-90. Review.

PMID:
21309117
40.

Effects of a positive allosteric modulator of group II metabotropic glutamate receptors, LY487379, on cognitive flexibility and impulsive-like responding in rats.

Nikiforuk A, Popik P, Drescher KU, van Gaalen M, Relo AL, Mezler M, Marek G, Schoemaker H, Gross G, Bespalov A.

J Pharmacol Exp Ther. 2010 Dec;335(3):665-73. doi: 10.1124/jpet.110.170506. Epub 2010 Aug 25.

41.

Double dissociation of the effects of haloperidol and the dopamine D3 receptor antagonist ABT-127 on acquisition vs. expression of cocaine-conditioned activity in rats.

Banasikowski TJ, Bespalov A, Drescher K, Behl B, Unger L, Haupt A, Schoemaker H, Sullivan JP, Gross G, Beninger RJ.

J Pharmacol Exp Ther. 2010 Nov;335(2):506-15. doi: 10.1124/jpet.110.171348. Epub 2010 Aug 19.

42.

Generation and therapeutic efficacy of highly oligomer-specific beta-amyloid antibodies.

Hillen H, Barghorn S, Striebinger A, Labkovsky B, Müller R, Nimmrich V, Nolte MW, Perez-Cruz C, van der Auwera I, van Leuven F, van Gaalen M, Bespalov AY, Schoemaker H, Sullivan JP, Ebert U.

J Neurosci. 2010 Aug 4;30(31):10369-79. doi: 10.1523/JNEUROSCI.5721-09.2010.

43.

Interaction of blockers of ionotropic NMDA receptors and metabotropic glutamate receptors in a working memory test in rats.

Novitskaya YA, Dravolina OA, Zvartau EE, Danysz W, Bespalov AY.

Neurosci Behav Physiol. 2010 Sep;40(7):807-11. doi: 10.1007/s11055-010-9330-4. Epub 2010 Jul 17.

PMID:
20635207
44.

Editorial for special issue on mGluRs and cognition.

Bespalov A.

Eur J Pharmacol. 2010 Aug 10;639(1-3):1. doi: 10.1016/j.ejphar.2010.03.049. Epub 2010 Apr 2. No abstract available.

PMID:
20363220
45.

[Behavioral mechanisms of nicotine dependence: a search for new drugs].

Dravolina OA, Bespalov AIu, Zakharova ES, Zvartau EE.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(7):73-81. Review. Russian. No abstract available.

PMID:
21465824
46.

[The prognostic role of interleukin-6 in peritoneal exudate of patients with diffuse peritonitis].

Plotkin LL, Bordunovskiĭ VN, Parfenova OV, Smirnov DM, Sachko AA, Bespalov AM.

Vestn Khir Im I I Grek. 2009;168(5):17-9. Russian.

PMID:
20020622
47.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

48.

[Effects of NMDA and metabotropic glutamate receptors antagonists in working memory task in rats].

Novitskaia IuA, Dravolina OA, Zvartau EE, Danysz W, Bespalov AIu.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2009 Jul-Aug;59(4):446-52. Russian.

PMID:
19795807
49.

Prevention of experimental stroke by hypercapnic-hypoxic preconditioning.

Yakushev NN, Bespalov AG, Kulikov VP.

Bull Exp Biol Med. 2008 Sep;146(3):289-90.

PMID:
19240841
50.

The state of cerebral hemodynamics in conditions of prolonged adaptation to hypercapnic hypoxia.

Kulikov VP, Bespalov AG, Yakushev NN.

Neurosci Behav Physiol. 2009 Mar;39(3):269-73. doi: 10.1007/s11055-009-9121-y. Epub 2009 Feb 21.

PMID:
19234804

Supplemental Content

Loading ...
Support Center